Last reviewed · How we verify
NCT05541757
Rivaroxaban - Percutaneous Coronary Intervention
trial testing In vitro heparin in Coronary Artery Disease in 30 participants. Completed in 1 March 2022.
1 January 2022
Quick facts
| Lead sponsor | Bursa Postgraduate Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 January 2021 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- In vitro heparin — full drug profile →
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
Sponsor
Bursa Postgraduate Hospital
Who can join
Adults 18 to 74, any sex, with Coronary Artery Disease or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We investigated in-vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention(PCI) while using regular direct oral anticoagulants(DOACs). Twenty-five patients taking 20mg of rivaroxaban once daily comprised the study group, while five healthy volunteers included the control group. In study group, a beginning(24-hours after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses(50IU/kg unfractionated heparin(UFH), 100IU/kg UFH, 0.5mg/kg enoxaparin, and 1mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th hours following rivaroxaban intake. Anticoagulant activity was assessed mainly by anti-factor Xa(anti-Xa) levels.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients.
Melek M, Ari H, Ari S, Cilgin MC, et al · · 2023 · PMID 37209152 · DOI 10.1007/s00210-023-02533-2 -
In Vitro Evaluation of Anticoagulant Therapy Management when Urgent Percutaneous Coronary Intervention is Required in Rivaroxaban-Treated Patients
MELEK M, ARI H, ARI S, CILGIN MC, et al · · 2023 · DOI 10.21203/rs.3.rs-2109990/v2
Verify or expand the search:
- PubMed search for NCT05541757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Bursa Postgraduate Hospital trials
Trials by the same sponsor.
- NCT07129122 — A Novel Technique for Percutaneous Mitral Paravalvular Leak Closure: LBBAP Lead Assisted Ventricular Septal Way · completed
- NCT06878638 — Nitrate - Clopidogrel - Acute Coronary Syndrome · completed
- NCT06951737 — Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients · completed
- NCT04507282 — Eosinophil and Anticoagulation in COVID-19 Patients · completed
- NCT04611386 — The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05541757 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bursa Postgraduate Hospital
- Last refreshed: 15 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05541757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing